Learning How Systemically Delivering Antisense Oligonucleotides Targeting CD49d RNA (ATL1102) Significantly Reduces New Active Brain Lesions in Patients With Relapse Remitting-Multiple Sclerosis

Time: 9:00 am
day: Day Two


  • Analyzing Pharmacodynamics: Focus on circulating white blood cell observations
  • Comprehensively analyzing safety data and pharmacokinetics
  • Deep diving into the pharmacology of ASOs in the brain